Abstract: Reinforcement learning of beam codebooks for millimeter wave and terahertz multiple-input-multiple-output (MIMO) systems is provided. Millimeter wave (mmWave) and terahertz (THz) MIMO systems rely on predefined beamforming codebooks for both initial access and data transmission. These predefined codebooks, however, are commonly not optimized for specific environments, user distributions, and/or possible hardware impairments. To overcome these limitations, this disclosure develops a deep reinforcement learning framework that learns how to optimize the codebook beam patterns relying only on receive power measurements. The developed model learns how to adapt the beam patterns based on the surrounding environment, user distribution, hardware impairments, and array geometry. Further, this approach does not require any knowledge about the channel, radio frequency (RF) hardware, or user positions.

Abstract: Provided herein are LILRB4-binding antibodies and methods of treating cancer by administering the LILRB4-binding antibodies alone or in combination with other therapies. Recombinant polypeptides comprising the CDRs of LILRB4-binding antibodies are also provided.

Abstract: A test capsule for measuring at least one property of a material exposed to nuclear radiation comprises a lattice structure configured to exhibit a change in at least one property responsive to exposure to nuclear radiation. The lattice structure comprises a first strut and a second strut connected to the first strut at a node. Related test capsules and methods are also described.

Abstract: Systems and methods for the generation and use of session keys supporting secure communications between a client and server device are disclosed. The client hashes each of a series of passwords a first number of times. The hashed passwords are sent to a server. The server applies the hashed password to an array of PUF devices, and receives an initial response bitstream which is stored. The client later hashes each of the series of passwords a second number of times, which is less than the first number, and these are sent to the server. The server continues to hash the second message digest, generate PUF responses, and compare the result to the initially stored responses. For each password, the number of hashes necessary to achieve a match is a partial session key. Latency is improved by an array of separately addressable PUFs, each producing a partial session key.

Abstract: Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and/or abscopal effects.

Abstract: Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.

Abstract: Aryl diimine first row metal compounds are described, as well as their synthesis and use as catalysts for the hydrofunctionalization of unsaturated organic compounds and main group element-main group element bond formation by dehydrogenative coupling.

Abstract: A system with an analyzer device in fluid communication with a sample of a bodily fluid is configured to chemically or electrochemically convert at least a portion of ammonium (NH4+) contained within the bodily fluid into ammonia (NH3) and dispel the converted ammonia (NH3) into a gas sensing chamber. An ammonia (NH3) sensor located within the gas sensing chamber in conjunction with a processor can quantify an amount of ammonia (NH3) present in the gas sensing chamber in relation to the total ammonia of the bodily fluid.

Abstract: Gold nanoparticles are conjugated to phosphatidylserine-specific ligands for targeting and binding to surface-exposed phosphatidylserine on tumor cells and tumor vasculature. The ligand may be an annexin (e.g., annexin V). Tumor contrast is significantly increased using the targeted gold nanoparticles. Breast cancer tumors as small as 4 mm, for example, were detectable via computed tomography (CT) within 4 hours after injection of the conjugates, demonstrating usefulness of the conjugates as imaging agents. The targeted gold nanoparticle conjugate may further have a drug conjugated thereto that can be used therapeutically, for example, for cancer treatment. The gold nanoparticle conjugates can also be used for photothermal therapy and can be used in concert with an X-ray radiation treatment for cancer treatment.

Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.

Abstract: Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display) are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide.

Abstract: 3D MRI images of the brain may be created and acquired. After administration of contrast, brain lesions and other abnormalities may be identified and isolated from the 3D MRI images, with each lesion serving as a region of interest (ROI). 3D region of contrast enhancement images may be created from segmented 3D MRI images and different regions of contrast enhancement of the brain lesion may be depicted. Saved regions of contrast enhancement may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D region of contrast enhancement images may be used to create 3D printed models of the isolated region of contrast enhancement. Analysis of the 3D brain region of contrast enhancement images and the 3D printed region of contrast enhancement models may enable a more efficient and accurate way of determining brain lesion risk factors and effective treatment regimens.

Abstract: An intravascular cutting device described herein uses high-pressure water, saline, or other fluid to cut tissue and other materials including but not limited to calcified tissue, stents, stent grafts, and other devices. In some embodiments, the cutting device includes a working end that has a nozzle with a hole to allow the release of a high-pressure fluid jet. Opposite of the nozzle is a catch plate or deflector anvil that prevents the fluid jet from cutting healthy tissue. The device user will place the item to be cut between the nozzle and catch plate and then advance the device along the item to be cut as the fluid jet is activated, thus cutting the object as it advances.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

Abstract: A steerable assembly comprises an elongated body structure with an implement arranged at a distal end thereof, wherein a premagnetized material is arranged closer to the distal end than a proximal end, and is configured to enable steering of the implement through tissue of an animal body responsive to application of a magnetic field eternal to the body. A method for guiding passage of an implement through tissue includes altering strength and/or position of at least one magnetic field source external to an animal body to interact with and effectuate movement of a premagnetized material inserted into the animal body.

Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.

Abstract: Devices and methods for extraction and processing of substantia gelatinea funiculi umbilicalis (Wharton's Jelly) from an umbilical cord.

Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.

Abstract: A method and composition for mitigating or reducing drug-induced ototoxicity or drug-induced hearing loss in a subject in need of such treatment, comprising: providing a drug delivery system which releases a therapeutic drug upon exposure to reactive oxygen species, wherein the drug delivery system comprises a thermoresponsive hydrogel containing therapeutic drug-loaded crosslinked hybrid nanoparticles and provides sustained therapeutic drug release. The crosslinked hybrid nanoparticles within which the therapeutic drug is loaded may comprise 10,12-Pentacosadiynoic acid (PCDA) and polypropylene sulfide-polyethylene glycol monomethyl ether (PPS-mPEG). The drug-induced ototoxicity or hearing loss may be caused by cisplatin or other platinum-based drugs.